阿帕替尼治疗甲状腺癌的疗效及对患者超声指标的改善效果分析  

Efficacy of Apatinib in the Treatment of Thyroid Cancer and Its Improvement Effect on Ultrasound Indexes

作　　者：王超[1] 杨欣[1] WANG Chao;YANG Xin(Jiamusi Central Hospital,Jiamusi 154000,Heilongjiang,China)

机构地区：[1]佳木斯市中心医院,黑龙江佳木斯154000

出　　处：《中国药物滥用防治杂志》2022年第9期1304-1308,共5页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探讨阿帕替尼治疗甲状腺癌的疗效及对患者超声指标改善效果的影响。方法:选取2020年1月—2022年1月本院收治的108例甲状腺癌患者为治疗对象,采用电脑随机抽签法分为观察组、对照组,各54例。对照组予以常规化疗治疗,观察组在对照组基础上联合阿帕替尼治疗。比较两组临床疗效、超声检查指标、甲状腺功能指标、血清学标记蛋白、治疗安全性。结果:观察组客观缓解率(ORR)、疾病控制率(DCR)高于对照组(P<0.05);观察组淋巴结最大径、淋巴结数量、钙化点数量均低于对照组(P<0.05);观察组三碘甲状腺素(FT3)、血清甲状腺素(FT4)低于对照组,促甲状腺激素(TSH)高于对照组(P<0.05);观察组甲状腺球蛋白(Tg)、甲状腺球蛋白抗体(TgAb)、蛋白激酶B(AKT)水平均低于对照组(P<0.05);观察组与对照组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿帕替尼治疗甲状腺癌的疗效显著,可降低淋巴结最大径、淋巴结数量、钙化点数量等超声指标,改善FT3、FT4、TSH等甲状腺功能指标,降低各项血清学标记蛋白水平,治疗安全性良好。Objective:To explore the therapeutic effect of apatinib on thyroid cancer and its influence on the improvement of ultrasonic indexes.Methods:A total of 108 patients with thyroid cancer admitted to our hospital from January 2020 to January 2022 were selected as the treatment objects.They were randomly divided into observation group and control group by computer lottery,with 54 cases in each group.The control group was treated with routine chemotherapy,and the observation group was treated with apatinib on the basis of the control group.The clinical efficacy,ultrasonic examination index,thyroid function index,serum marker protein and treatment safety were compared between the two groups.Results:The objective remission rate(ORR)and disease control rate(DCR)of the observation group were higher than those of the control group(P<0.05).The maximum diameter of lymph nodes,the number of lymph nodes and the number of calcifications in the observation group were lower than those in the control group(P<0.05).The levels of triiodothyroxine(FT3)and serum thyroxine(FT4)in the observation group were lower than those in the control group,and the levels of thyroid stimulating hormone(TSH)were higher than those in the control group(P<0.05).The levels of thyroglobulin(TG),thyroglobulin antibody(TGAb)and protein kinase B(Akt)in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:Apatinib has a significant effect in treating thyroid cancer.It can reduce the maximum diameter of lymph nodes,the number of lymph nodes,the number of calcified spots and other ultrasound indicators,improve the thyroid function indicators such as FT3,FT4 and TSH,and reduce the level of various serological marker proteins.The treatment is safe.

关 键 词：甲状腺癌 阿帕替尼 超声检查 临床疗效 甲状腺功能 

分 类 号：R736.1[医药卫生—肿瘤]